Vivo Capital LLC Reduces Stake in Selecta Biosciences Inc (SELB)

Vivo Capital LLC decreased its holdings in Selecta Biosciences Inc (NASDAQ:SELB) by 2.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 761,253 shares of the company’s stock after selling 19,348 shares during the period. Selecta Biosciences comprises 1.2% of Vivo Capital LLC’s portfolio, making the stock its 22nd largest holding. Vivo Capital LLC owned about 3.39% of Selecta Biosciences worth $11,837,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Rhumbline Advisers boosted its holdings in Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after buying an additional 5,103 shares during the last quarter. Virtu Financial LLC bought a new position in Selecta Biosciences during the third quarter worth about $363,000. Schwab Charles Investment Management Inc. boosted its holdings in Selecta Biosciences by 37.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock worth $447,000 after buying an additional 9,100 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Selecta Biosciences by 27.2% during the second quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock worth $626,000 after buying an additional 10,114 shares during the last quarter. Finally, Proxima Capital Management LLC bought a new position in Selecta Biosciences during the second quarter worth about $1,075,000. Institutional investors own 51.04% of the company’s stock.

Shares of NASDAQ:SELB traded up $0.10 during trading on Monday, hitting $6.13. 5,590 shares of the company’s stock traded hands, compared to its average volume of 117,312. Selecta Biosciences Inc has a 52 week low of $4.74 and a 52 week high of $16.55. The stock has a market capitalization of $135.28 million, a PE ratio of -1.92 and a beta of 0.98.

Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. Equities analysts anticipate that Selecta Biosciences Inc will post -2.92 earnings per share for the current year.

SELB has been the topic of a number of recent analyst reports. Mizuho restated a “buy” rating and set a $30.00 target price on shares of Selecta Biosciences in a report on Monday, November 5th. BidaskClub upgraded Selecta Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 9th. Stifel Nicolaus initiated coverage on Selecta Biosciences in a report on Friday, September 14th. They set a “buy” rating and a $24.00 target price on the stock. Janney Montgomery Scott restated a “buy” rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd. Finally, Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a report on Thursday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $23.21.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2018/12/03/vivo-capital-llc-reduces-stake-in-selecta-biosciences-inc-selb.html.

Selecta Biosciences Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Featured Story: Analyst Ratings

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit